📊 Evidence-Based Reference

Viewray Treatment Planning and Delivery System

Viewray

Compare similar devices

Summary: The Viewray treatment planning and delivery system is a medical device used for radiotherapy, integrating MRI for precise treatment planning. Key evidence highlights its use in prostate cancer and spine metastases treatment.

FDA Clearance Information

Pathway ? 510(k)
Number ? K102915 ↗
Decision Date ? January 12, 2011
Product Code ? MUJ
Device Class ? Class 2
Evidence ? 0 studies

The Viewray treatment planning and delivery system was cleared by the FDA through the 510(k) pathway on January 12, 2011. It is manufactured by Viewray and classified as a Class 2 device under product code MUJ.

What It Is

The Viewray system is a radiotherapy device that combines magnetic resonance imaging (MRI) with radiation delivery for precise treatment planning and execution. It is intended for use in radiotherapy to enhance the accuracy of tumor targeting while minimizing exposure to surrounding healthy tissues.

FDA-Cleared Indications

  • Radiation treatment planning and delivery for patients requiring radiotherapy.
  • Use of MRI guidance to support localization and targeting of treatment areas.
  • Treatment of malignant tumors in anatomical regions that can be imaged and treated by the system.

Clinical Applications

  • MRI-guided external-beam radiotherapy planning.
  • MRI-guided radiation treatment delivery for malignant tumors.
  • Image-guided targeting and monitoring during radiotherapy.
  • Adaptive radiotherapy planning when tumor position or nearby anatomy changes during treatment.

Reported off-label uses

  • MRI-guided stereotactic or hypofractionated treatment protocols in selected patients.
  • MRI-guided treatment of prostate cancer and spine metastases when performed under an institutionally approved protocol.

Off-label use: these uses are reported in practice or the literature but are not part of the FDA-cleared indications. Physicians may use a cleared device off-label based on their medical judgment; the manufacturer may not promote off-label uses.

Evidence Summary

The available literature includes 15 studies, comprising randomized controlled trials, prospective and retrospective analyses, and case series. The studies span from 2023 to 2025, focusing on various cancer treatments using the Viewray system.

Reported Outcomes

Published studies report that the Viewray system enhances the precision of radiotherapy in prostate cancer and spine metastases, with improved targeting accuracy and potential for reduced treatment times. Outcomes in prostate cancer show promising results with hypofractionated schedules.

Safety Profile

Reported complications include cardiotoxicity in lung cancer patients undergoing thoracic radiotherapy, highlighting the need for careful monitoring of cardiac health. No other significant adverse events were noted in the provided evidence.

Evidence Limitations

The evidence is limited by the small number of large-scale randomized controlled trials and the variability in clinical workflows across different studies. Further research is needed to standardize treatment protocols and assess long-term outcomes.

Practical Considerations

  • The system combines an MRI scanner with a radiation-delivery system; treatment requires staff trained in both MRI safety and radiotherapy.
  • MRI-related contraindications and precautions apply, including certain implanted devices, metallic foreign bodies, and inability to remain still or follow breath-hold instructions.
  • Treatment planning must account for magnetic-field effects, patient positioning, imaging artifacts, and the compatibility of immobilization equipment and accessories.
  • The treatment field, patient size, and ability to position the target within the system can limit which tumors can be treated.
  • Treatment duration and the number of sessions vary with the cancer, prescribed radiation dose, imaging requirements, and whether adaptive replanning is needed.

Frequently Asked Questions

What are the clinical indications for Viewray treatment planning and delivery system?

The Viewray system is indicated for use in radiotherapy, particularly in treating prostate cancer and spine metastases, where precise imaging and adaptive planning are essential.

What outcomes have been reported in clinical studies?

Clinical studies have reported improved targeting accuracy and potential for reduced treatment times in prostate cancer and spine metastases using the Viewray system.

What complications have been reported?

Safety data indicate cardiotoxicity as a complication in lung cancer patients undergoing thoracic radiotherapy, necessitating careful cardiac monitoring.

Disclaimer: This page compiles publicly available regulatory and published clinical evidence for educational reference. It does not constitute medical advice, product endorsement, or a recommendation for clinical use. Always consult manufacturer documentation and clinical judgment for patient care decisions.

📬 The IR Device Brief

One email a month: new FDA clearances, recalls and device pages in vascular & interventional radiology.

We'll email you a link to confirm. Unsubscribe any time.

Suggest edits

For manufacturers and their teams. Each field shows what the page says now: add, remove or rewrite anything, and leave the rest as is. LA Vascular reviews every change before it goes live.

About you